Andelyn Biosciences is a specialized gene therapy CDMO founded in 2020, with roots in pioneering research and a substantial track record, including involvement in an approved gene therapy. It operates three facilities totaling 225,000 square feet and has supported over 75 INDs and 450 cGMP clinical batches. The company differentiates itself through its data-driven AAV Curator® and DIGITAL CDMO® platforms, aiming to reduce costs and accelerate timelines for client programs from concept to commercialization.
Rare DiseasesGenetic Disorders
Technology Platform
Proprietary AAV Curator® Platform using Optimization-By-Design™ methodology and the DIGITAL CDMO® Platform for data-driven development and manufacturing.
Funding History
2
Total raised:$59.5M
Series A$55MDrive Capital
Grant$4.5MNational Institute of Neurological Disorders and Stroke
Opportunities
Explosive growth in the cell and gene therapy market creates massive demand for specialized CDMO services.
Andelyn's proprietary AAV Curator® Platform offers a differentiated value proposition to reduce costs and timelines, potentially capturing significant market share.
Expansion into late-stage and commercial manufacturing for partners represents a high-value service tier.
Risk Factors
Intense competition from other CDMOs and potential in-house manufacturing by large pharma.
Revenue is dependent on the clinical success of client programs, which are high-risk.
The capital-intensive nature of the business requires continuous investment and poses execution risks in scaling facilities and maintaining quality.
Competitive Landscape
Andelyn competes in a crowded gene therapy CDMO space against large players like Lonza, Catalent, and Thermo Fisher Scientific, as well as specialized peers like Oxford Biomedica and Brammer Bio. Its differentiation is based on deep legacy experience, a focus on AAV, and proprietary data-driven platforms aimed at process optimization.
